Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis

Drugs

Volumn 65, Issue 17, 2005, Pages 2429-2436

  Lenz, Oliver ^a   Fornoni, Alessia ^a   Contreras, Gabriel ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VASCULAR CELL ADHESION MOLECULE 1;

AMENORRHEA; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; KIDNEY FUNCTION; LEUKOCYTE MIGRATION INHIBITION; LUPUS ERYTHEMATOSUS NEPHRITIS; OVARY INSUFFICIENCY; POLYCLONAL ACTIVATION; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

AZATHIOPRINE; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; LUPUS NEPHRITIS; MYCOPHENOLIC ACID;

HERPES ZOSTER;

EID: 28144451020     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565170-00001     Document Type: Review

References (71)

1. Uramoto KM, Michet Jr CJ, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42: 46-50
2. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 778-99
3. Hochberg MC. The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970-1977. Arthritis Rheum 1985; 28: 80-6
4. McCarty DJ, Manzi S, Medsger Jr TA, et al. Incidence of systemic lupus erythematosus: race and gender differences. Arthritis Rheum 1995; 38: 1260-70
5. Siegel M, Holley HL, Lee SL. Epidemiologic studies on systemic lupus erythematosus: comparative data for New York City and Jefferson County, Alabama, 1956-1965. Arthritis Rheum 1970; 13: 802-11
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725
7. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-24
8. Pollak VE, Pirani CL, Schwartz FD. The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 1964; 63: 537-50
9. McCluske RT. Lupus nephritis. In: Sommer SC, editor. Kidney pathology decennial 1966-1975. East Norwalk (CT): Appleton-Century-Crofts, 1975: 435-50
10. Morel-Maroger L, Mery JP, Droz D, et al. The course of lupus nephritis: contribution of serial renal biopsies. Adv Nephrol Necker Hosp 1976; 6: 79-118
11. Austin III HA, Muenz LR, Joyce KM, et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-95
12. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-30
13. Appel GB, Cohen DJ, Pirani CL, et al. Long-term follow-up of patients with lupus nephritis: a study based on the classification of the World Health Organization. Am J Med 1987; 83: 877-85
14. Austin III HA, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med 1983; 75: 382-91
15. Austin III HA, Boumpas DT, Vaughan EM, et al. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995; 10: 1620-8
16. Levey AS, Lan SP, Corwin HL, et al. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study: results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 1992; 116: 114-23
17. Pasquali S, Banfi G, Zucchelli A, et al. Lupus membranous nephropathy: long-term outcome. Clin Nephrol 1993; 39: 175-82
18. Radhakrishnan J, Kunis CL, D'Agati V, et al. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994; 42: 147-54
19. Schwartz MM, Lewis EJ. Rewriting the histological classifica-tion of lupus nephritis. J Nephrol 2002; 15 Suppl. 6: S11-9
20. Cathcart ES, Idelson BA, Scheinberg MA, et al. Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis. Lancet 1976; I: 163-6
21. Dosa S, Cairns SA, Lawler W, et al. The treatment of lupus nephritis by methyl prednisolone pulse therapy. Postgrad Med J 1978; 54: 628-32
22. Ponticelli C, Zucchelli P, Banfi G, et al. Treatment of diffuse proliferative lupus nephritis by intravenous high-dose methylprednisolone. Q J Med 1982; 51: 16-24
23. Austin III HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9
24. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991; 34: 945-50
25. Gourley MF, Austin III HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996; 125: 549-57
26. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-57
27. Boumpas DT, Austin III HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-5
28. Flanc RT, Roberts MA, Strippoli GFM, et al. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled clinical trials. Am J Kidney Dis 2004; 43: 197-208
29. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-31
30. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50: 3934-40
31. Lee WA, Gu L, Miksztal AR, et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990; 7: 161-6
32. Allison AC, Hovi T, Watts RW, et al. Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation. Lancet 1975; II: 1179-83
33. Giblett ER, Anderson JE, Cohen F, et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; II: 1067-9
34. Allison AC, Almquist SJ, Muller CD, et al. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 1991; 23: 10-4
35. Carr SF, Papp E, Wu JC, et al. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993; 268: 27286-90
36. Eugui EM, Almquist SJ, Muller CD, et al. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33: 161-73
37. Grailer A, Nichols J, Hullett D, et al. Inhibition of human B cell responses in vitro by RS-61443, cyclosporine A and DAB486 IL-2. Transplant Proc 1991; 23: 314-5
38. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991; 33: 175-83
39. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118
40. McMurray RW. Adhesion molecules in autoimmune disease. Semin Arthritis Rheum 1996; 25: 215-33
41. Harari OA, Marshall D, McHale JF, et al. Limited endothelial E-and P-selectin expression in MRL/lpr lupus-prone mice. Rheumatology (Oxford) 2001; 40: 889-95
42. McHale JF, Harari OA, Marshall D, et al. TNF-alpha and IL-1 sequentially induce endothelial ICAM-1 and VCAM-1 expression in MRL/lpr lupus-prone mice. J Immunol 1999; 163: 3993-4000
43. Wuthrich RP. Vascular cell adhesion molecule-1 (VCAM-1) expression in murine lupus nephritis. Kidney Int 1992; 42: 903-14
44. Wuthrich RP, Jevnikar AM, Takei F, et al. Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated in autoimmune murine lupus nephritis. Am J Pathol 1990; 136: 441-50
45. Van Bruggen MC, Walgreen B, Rijke TP, et al. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998; 9: 1407-15
46. McMurray RW, Elbourne KB, Lagoo A, et al. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus. J Rheumatol 1998; 25: 2364-70
47. Muller V, Hamar P, Szabo A, et al. Effect of mycophenolate mofetil on the in vivo infiltration of lymphocytes in the rat remnant kidney. Transplant Proc 1998; 30: 982
48. Fujihara CK, Malheiros DM, Zatz R, et al. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998; 54: 1510-9
49. Romero F, Rodriguez-Iturbe B, Parra G, et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999; 55: 945-55
50. Ziswiler R, Steinmann-Niggli K, Kappeler A, et al. Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1998; 9: 2055-66
51. Noronha IL, Fujihara CK, Oliveira IB, et al. Enhanced interstitial expression of angiotensin II and TGFβ in the renal ablation model: effect of mycophenolate mofetil [abstract]. J Am Soc Nephrol 1998; 9: 618A
52. Klinman DM, Shirai A, Ishigatsubo Y, et al. Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus. Arthritis Rheum 1991; 34: 1404-10
53. Linker-Israeli M, Quismorio Jr FP, Horwitz DA. CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 1990; 33: 1216-25
54. Bakke AC, Kirkland PA, Kitridou RC, et al. T lymphocyte subsets in systemic lupus erythematosus. Correlations with corticosteroid therapy and disease activity. Arthritis Rheum 1983; 26: 745-50
55. Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 833-9
56. Karim MY, Alba P, Cuadrado MJ, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002; 41: 876-23
57. Kingdon EJ, McLean AG, Psimenou E, et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001; 10: 606-11
58. Buratti S, Szer IS, Spencer CH, et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 28: 2103-8
59. Fu YF, Liu GL. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclophosphamide and cyclosporine. Clin Nephrol 2001; 55: 318-21
60. Gaubitz M, Schorat A, Schotte H, et al. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8: 731-6
61. Briggs WA, Choi MJ, Scheel Jr PJ. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998; 31: 213-7
62. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998; 32: 318-22
63. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis: Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-62
64. Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-84
65. Hu W, Liu Z, Chen H, et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse prolifera-tive lupus nephritis. Chin Med J (Engl) 2002; 115: 705-9
66. Ginzler EM, Aranow C, Buyon J, et al. A multicenter study of mycophenolate mofetil (MMF) vs intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN): preliminary results [abstract]. Arthritis Rheum 2003; 48: S647
67. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-80
68. Houssiau FA. Management of lupus nephritis: an update. J Am Soc Nephrol 2004; 15 (10): 2694-704
69. Grootscholten C, Ligtenberg G, van Houwelingen HC, et al. Randomized controlled trial comparing cyclophosphamide pulse therapy with azathioprine/methylprednisolone in proliferative lupus nephritis [abstract no. SU-FC047]. Ameri-can Society of Nephrology Renal Week; 2004 Oct 24-Nov 1; St Louis (MO)
70. Lenz O, Contreras G. Treatment options for severe lupus nephri-tis. Arch Immunol Ther Exp (Warsz) 2004; 52: 356-65
71. Aspreva Lupus Management Study (ALMS). ClinicalTrials.gov identifier: NCT00121082 [online]. Available from URL: http://ClinicalTrials.gov [Accessed 2005 Sep 14]